Published 1 day ago • loading... • Updated 14 hours ago

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice

The US Food and Drug Administration has removed semaglutide from its shortage list, allowing broader access to the medications Ozempic and Wegovy, which treat diabetes and obesity.
Novo Nordisk is now able to meet the current and future demand for the medications, as stated by the FDA.
The FDA has set deadlines for compounders to stop producing the drug by April 22 and May 22, 2025, for different types of compounders.
Federal regulators acknowledged that patients may still experience some supply disruptions when medications are distributed to pharmacies.

Insights by Ground AI

Does this summary seem wrong?

52 Articles

All

Left

Center

Right

WLKY

+7 Reposted by 7 other sources

Shortage of popular weight-loss, diabetes drugs is resolved, FDA says

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.

15 hours ago·Louisville, United States

Read Full Article

The Hill

Ozempic and Wegovy officially moved off FDA’s drug shortage list

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list nearly four months after the agency found the drugs to be available. The FDA’s drug shortage list now states that as of Feb. 21, 2025, the…

16 hours ago·Washington, United States

Read Full Article

Origo

Ozempic is a hit, pharmaceutical sales account for half of Denmark's GDP

Two years ago, Danish company Novo Nordisk was barely known, but today the company's market value has skyrocketed, thanks to the outstanding sales of the drugs Wegovy and Ozempic. Sales of anti-obesity and diabetes drugs have grown tremendously, making the company one of the most valuable companies in Europe.

17 hours ago·Budapest, Hungary

Read Full Article

MedPage Today

Ozempic, Wegovy Shortage Is Officially Over

(MedPage Today) -- The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current and projected U.S. demand...

19 hours ago·New York, United States

Read Full Article